NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Forced Titration, Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of 60 mg and 120 mg of GW679769 administered once daily vs Placebo in Women with Overactive Bladder
Inclusion Criteria:
Exclusion Criteria: